Omeros Corporation today announced two presentations that will be featured at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and ...
3h
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback